These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 8927235)

  • 1. Changes in late auditory evoked potentials induced by corticotropin-releasing hormone and corticotropin fragment 4-9 in male controls.
    Hartmann A; Krumrey K; Vogl L; Dirlich G; Holsboer F; Heuser-Link M
    Neuropsychobiology; 1996; 33(2):90-6. PubMed ID: 8927235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influences of peripheral adrenocorticotropin 1-39 (ACTH) and human corticotropin releasing hormone (h-CRH) on human auditory evoked potentials (AEP).
    Born J; Bathelt B; Pietrowsky R; Pauschinger P; Fehm HL
    Psychopharmacology (Berl); 1990; 101(1):34-8. PubMed ID: 2160665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The relationship of saline-induced changes in vasopressin secretion to basal and corticotropin-releasing hormone-stimulated adrenocorticotropin and cortisol secretion in man.
    Rittmaster RS; Cutler GB; Gold PW; Brandon DD; Tomai T; Loriaux DL; Chrousos GP
    J Clin Endocrinol Metab; 1987 Feb; 64(2):371-6. PubMed ID: 3025246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of corticotropin releasing hormone on human brain function: an analysis based on auditory evoked potentials.
    Fehm HL; Born J
    Horm Metab Res Suppl; 1987; 16():75-9. PubMed ID: 2832298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in late auditory evoked potentials induced by growth hormone-releasing hormone (GHRH) but not somatostatin (SRIF) after peripheral administration in male controls.
    Hartmann A; Dietl T; Krumrey K; Vogl L; Dirlich G; Holsboer F; Heuser-Link M
    Peptides; 1995; 16(4):657-63. PubMed ID: 7479300
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Brain evoked responses, a bioassay for central actions of adrenocorticotropin (ACTH 1-39) and corticotropin releasing hormone (CRH) in humans.
    Born J; Seidel E; Pietrowsky R; Fehm HL
    Horm Metab Res; 1991 Mar; 23(3):126-30. PubMed ID: 1650750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comparison of the effects of human and ovine corticotropin-releasing hormone on the pituitary-adrenal axis.
    Trainer PJ; Faria M; Newell-Price J; Browne P; Kopelman P; Coy DH; Besser GM; Grossman AB
    J Clin Endocrinol Metab; 1995 Feb; 80(2):412-7. PubMed ID: 7852498
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of endogenous arginine vasopressin in potentiating corticotropin-releasing hormone-stimulated corticotropin secretion in man.
    Watabe T; Tanaka K; Kumagae M; Itoh S; Kogure M; Hasegawa M; Horiuchi T; Morio K; Takeda F; Ubukata E
    J Clin Endocrinol Metab; 1988 Jun; 66(6):1132-7. PubMed ID: 2836468
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of synthetic ovine corticotropin-releasing hormone on plasma concentrations of immunoreactive adrenocorticotropin, alpha-melanocyte-stimulating hormone, and cortisol in dogs with naturally acquired adrenocortical insufficiency.
    Peterson ME; Kemppainen RJ; Orth DN
    Am J Vet Res; 1992 Mar; 53(3):421-5. PubMed ID: 1317690
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to corticotropin-releasing hormone during pregnancy in the baboon.
    Goland RS; Stark RI; Wardlaw SL
    J Clin Endocrinol Metab; 1990 Apr; 70(4):925-9. PubMed ID: 2156891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessment of stimulated and spontaneous adrenocorticotropin secretory dynamics identifies distinct components of cortisol feedback inhibition in healthy humans.
    Dorin RI; Ferries LM; Roberts B; Qualls CR; Veldhuis JD; Lisansky EJ
    J Clin Endocrinol Metab; 1996 Nov; 81(11):3883-91. PubMed ID: 8923833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Responses induced by arginine-vasopressin injection in the plasma concentrations of adrenocorticotropic hormone, cortisol, growth hormone and metabolites around weaning time in goats.
    Katoh K; Yoshida M; Kobayashi Y; Onodera M; Kogusa K; Obara Y
    J Endocrinol; 2005 Nov; 187(2):249-56. PubMed ID: 16293772
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuous administration of human corticotropin-releasing hormone in the absence of glucocorticoid feedback in man.
    Ur E; Capstick C; McLoughlin L; Checkley S; Besser GM; Grossman A
    Neuroendocrinology; 1995 Feb; 61(2):191-7. PubMed ID: 7753338
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of ovine corticotropin-releasing hormone on adrenocorticotropin secretion in the absence of glucocorticoid feedback inhibition in man.
    Debold CR; Jackson RV; Kamilaris TC; Sheldon WR; Decherney GS; Island DP; Orth DN
    J Clin Endocrinol Metab; 1989 Feb; 68(2):431-7. PubMed ID: 2537333
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of prostaglandin E2 (PGE2) on the corticotropin-releasing hormone (CRH)-induced ACTH release in healthy men.
    Zacharieva S; Borissova AM; Andonova K; Stoeva I; Matrozov P
    Horm Metab Res; 1992 Jul; 24(7):336-8. PubMed ID: 1325403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alprazolam attenuates vasopressin-stimulated adrenocorticotropin and cortisol release: evidence for synergy between vasopressin and corticotropin-releasing hormone in humans.
    Torpy DJ; Grice JE; Hockings GI; Walters MM; Crosbie GV; Jackson RV
    J Clin Endocrinol Metab; 1994 Jul; 79(1):140-4. PubMed ID: 8027217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Responsivity of adrenocorticotropin to corticotropin-releasing hormone and lack of suppressibility by dexamethasone are related phenomena in Cushing's disease.
    Hermus AR; Pieters GF; Pesman GJ; Smals AG; Benraad TJ; Kloppenborg PW
    J Clin Endocrinol Metab; 1986 Apr; 62(4):634-9. PubMed ID: 3005353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-response relationships between plasma adrenocorticotropin (ACTH), cortisol, aldosterone, and 18-hydroxycorticosterone after injection of ACTH-(1-39) or human corticotropin-releasing hormone in man.
    Oelkers W; Boelke T; Bähr V
    J Clin Endocrinol Metab; 1988 Jan; 66(1):181-6. PubMed ID: 2826525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of exogenous atrial natriuretic peptide on the pituitary-adrenal response to corticotropin-releasing hormone and vasopressin in healthy men.
    Bierwolf C; Burgemeister A; Lüthke K; Born J; Fehm HL
    J Clin Endocrinol Metab; 1998 Apr; 83(4):1151-7. PubMed ID: 9543132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of repetitive administration of corticotropin-releasing hormone combined with lysine vasopressin on plasma adrenocorticotropin and cortisol levels in secondary adrenocortical insufficiency.
    Fukata J; Usui T; Tsukada T; Nakai Y; Koh T; Ishihara T; Tanaka I; Uchida K; Yoshimasa T; Nakano R
    J Clin Endocrinol Metab; 1990 Dec; 71(6):1624-31. PubMed ID: 2172283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.